RxDoctor Payments Data

Alison Bailey, MD

Advanced Heart Failure and Transplant Cardiology · Gainesville, GANPI 1992715502

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (42.5%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. 50 manufacturers reported payments, led by E.r. Squibb & Sons, L.L.C. at 33.1% of the total. 2025 is the largest year on record at $11,508, 3.9 times the $2,935 reported in 2019.

$27,567in general payments, 2019–2025

Across 401 payments — averaging $68.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$9K
  • Medtronic$5K
  • GE HealthCare$3K
  • CSL Behring$2K
  • Novartis$1K
  • Actelion Pharmaceuticals US, Inc.$768
  • plus $5K from 44 others
$13,750in research payments, 2019–2025

Across 5 payments — averaging $2750.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • CSL Behring$14K

What the payments were for

  • Consulting fees$11,71743%
  • Speaking & faculty fees$3,58813%
  • Travel & lodging$3,41312%
  • Food & beverage$8,68832%
  • Education$1611%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$27,567 in reported general payments places this provider in the 65th percentile of 40 advanced heart failure and transplant cardiology providers in Georgia.

See all advanced heart failure and transplant cardiology providers in Georgia

Medicare billing

Part B allowed, 2024
$142,026
Medicare patients
829
Services billed
3,399

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide183$199,475
JardianceEmpagliflozin213$184,671
EliquisApixaban205$177,525
FarxigaDapagliflozin Propanediol179$136,604
EntrestoSacubitril/Valsartan121$124,098
MounjaroTirzepatide87$109,316
XareltoRivaroxaban79$67,757
Repatha SureclickEvolocumab35$38,477
WegovySemaglutide16$21,949
VascepaIcosapent Ethyl20$10,659
Dilt-XrDiltiazem Hcl126$5,854
Valsartan64$4,373
NexletolBempedoic Acid11$4,173
Spironolactone418$3,644
Metoprolol Succinate181$3,394

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Wegovy$270$221,425199 claims
Boehringer IngelheimJardiance$270$184,671213 claims
PfizerEliquis$606$177,525205 claims
AstraZenecaFarxiga$196$136,604179 claims
NovartisEntresto$1,396$124,098121 claims
Lilly USA, LLCMounjaro$16$109,31687 claims
Johnson & JohnsonXarelto$399$67,75779 claims
Esperion Therapeutics, Inc.Nexletol$154$4,17311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 40 advanced heart failure and transplant cardiology providers in Georgia.

Other advanced heart failure and transplant cardiology in Gainesville

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →